Rocket Pharmaceuticals (RCKT) Common Equity (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Common Equity of $238.0 million for Q1 2026, down 14.13% sequentially from $277.2 million in Q4 2025, and down 42.24% YoY from $412.1 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Common Equity (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Common Equity for 13 years, with the latest figure at $238.0 million in Q1 2026.
- Quarterly Common Equity fell 42.24% year-over-year to $238.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $238.0 million (down 42.24% YoY) and the FY2025 annual result came in at $277.2 million, down 40.16% from the prior year.
- Common Equity slipped to $238.0 million in Q1 2026 per RCKT's latest filing, from $277.2 million in the prior quarter.
- Over five years, Common Equity peaked at $541.1 million in Q3 2023 and troughed at $238.0 million in Q1 2026.
- A 5-year average of $398.4 million and a median of $403.0 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2026: Common Equity soared 47.31% in 2023, then plunged 42.24% in 2026.
- Over 5 years, Common Equity stood at $489.7 million in 2022, then grew by 0.59% to $492.6 million in 2023, then dropped by 5.96% to $463.2 million in 2024, then plunged by 40.16% to $277.2 million in 2025, then retreated by 14.13% to $238.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $238.0 million, $277.2 million, and $313.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - | 368.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 368.83 Mn |
| Mar 31, 2026 | 238.04 Mn |
| Dec 31, 2025 | 277.22 Mn |
| Sep 30, 2025 | 313.67 Mn |
| Jun 30, 2025 | 354.21 Mn |
| Mar 31, 2025 | 412.14 Mn |
| Dec 31, 2024 | 463.23 Mn |
| Sep 30, 2024 | 329.77 Mn |
| Jun 30, 2024 | 384.64 Mn |
| Mar 31, 2024 | 441.50 Mn |
| Dec 31, 2023 | 492.57 Mn |
| Sep 30, 2023 | 541.09 Mn |
| Jun 30, 2023 | 402.97 Mn |
| Mar 31, 2023 | 458.88 Mn |
| Dec 31, 2022 | 489.69 Mn |
| Sep 30, 2022 | 367.31 Mn |
| Jun 30, 2022 | 387.70 Mn |
| Mar 31, 2022 | 417.62 Mn |
| Dec 31, 2021 | 454.72 Mn |
| Sep 30, 2021 | 485.66 Mn |